UBI Ubisoft Entertainment SA

DISCLOSURE OF TRADING IN OWN SHARES PRE-PAID FORWARD AGREEMENT ON OWN SHARES

DISCLOSURE OF TRADING IN OWN SHARES PRE-PAID FORWARD AGREEMENT ON OWN SHARES

DISCLOSURE OF TRADING IN OWN SHARES

PRE-PAID FORWARD AGREEMENT ON OWN SHARES

(partial early settlement)

Paris, September 15, 2022 – Ubisoft Entertainment SA (Euronext Paris: UBI – ISIN code FR0000054470) has decided on September 8, 2022, by virtue of the opportunity offered under the terms of the pre-paid forward agreement entered into on March 20, 2018 with Crédit Agricole Corporate and Investment Bank (the "Agreement")1, to settle by anticipation the Agreement for an amount of 1,000,000 treasury shares (the "Shares") out of the remaining balance under the Agreement of 3,445,454 Shares1(a).

The delivery of the Shares (in pure registered form) on September 15, 2022 to Caceis Corporate Trust, is part of the share buyback program authorized by the General Meeting of Ubisoft Entertainment SA on July 5, 2022.

These Shares are intended to be used to cover employee shareholding plans, in particular in connection with the 2022 employee shareholding operation (reserved sales of existing shares).

Issuer corporate

name
Issuer identification codeSettlementPurchase/SaleOptions/Futures
Ubisoft Entertainment sa969500I7C8V1LBIMSM05September 8, 2022PurchasePartial early settlement of the pre-paid forward agreement by delivery of the shares



Number of sharesFinancial instrument identification codeDeliveryMarketPurpose of the purchases
1,000,000FR0000054470September 15, 2022Over the counterEmployee share ownership plans coverage

This operation has no impact in terms of dilution or on Ubisoft Entertainment SA’s net cash position.



Contacts Ubisoft

Investor Relations

Jean-Benoît Roquette

SVP Investor Relations

39

Alexandre Enjalbert

Senior Investor Relations Manager

78



Press Relations

Michael Burk

VP Corporate Public Relations

03



About Ubisoft

Ubisoft is a creator of worlds, committed to enriching players’ lives with original and memorable entertainment experiences. Ubisoft’s global teams create and develop a deep and diverse portfolio of games, featuring brands such as Assassin’s Creed®, Brawlhalla®, For Honor®, Far Cry®, Tom Clancy’s Ghost Recon®, Just Dance®, Rabbids®, Tom Clancy’s Rainbow Six®, The Crew®, Tom Clancy’s The Division®, and Watch Dogs®. Through Ubisoft Connect, players can enjoy an ecosystem of services to enhance their gaming experience, get rewards and connect with friends across platforms. With Ubisoft+, the subscription service, they can access a growing catalog of more than 100 Ubisoft games and DLC. For the 2021–22 fiscal year, Ubisoft generated net bookings of €2,129 million. To learn more, please visit:






1 to be settled at maturity (March 22, 2024) [(a) Cf. "" - September 15, 2020] or by anticipation, in whole or in part, by Ubisoft Entertainment SA [(b) Cf. "" - March 20, 2018 / (c) Cf. "" - March 29, 2018]



Attachment



EN
15/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ubisoft Entertainment SA

Wedbush Research
  • Wedbush Research
W WAYFAIR INC.
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TRIP TRIPADVISOR INC.
SRPT SAREPTA THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
EXPE EXPEDIA GROUP INC.
ETSY ETSY INC.
EBAY EBAY INC.
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
SE SEA ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
BKNG BOOKING HOLDINGS INC.
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
CHWY CHEWY INC. CLASS A
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
KROS ADICET BIO INC
ZNTL KEROS THERAPEUTICS
BEAM ZENTALIS PHARMACEUTICALS
LRMR BEAM THERAPEUTICS
OCUP LARIMAR THERAPEUTICS INC
PRAX OCUPHIRE PHARMA INC
COGT PRAXIS PRECISION MEDICINES
U COGENT BIOSCIENCES INC
TVTX UNITY SOFTWARE
DASH TRAVERE THERAPEUTICS INC
ABNB DOORDASH
VRDN AIRBNB INC. CLASS A
PLTK VIRIDIAN THERAPEUTICS INC
NUVB PLAYTIKA HOLDING
RBLX NUVATION BIO INC (A)
DAWN ROBLOX
TNGX DAY ONE BIOPHARMACEUTICALS INC
STX TANGO THERAPEUTICS
HOWL INC
APP SEAGATE TECHNOLOGY HLDGS PLC
TTD WEREWOLF THERAPEUTICS INC
QUBT APPLOVIN CORP
GFS THE TRADE DESK
GMTX INC.
TYRA QUANTUM COMPUTING INC
EWTX GLOBALFOUNDRIES INC
SLDB GEMINI THERAPEUTICS INC
DDI TYRA BIOSCIENCES INC
APGE EDGEWISE THERAPEUTICS INC
EMBRAC B SOLID BIOSCIENCES INC
DNTH DOUBLEDOWN INTERACTIVE CO LTD
CART APOGEE THERAPEUTICS INC
NATL EMBRACER GROUP AB
CGON DIANTHUS THERAPEUTICS INC
ORKA MAPLEBEAR INC.
BCAX NCR ATLEOS CORPORATION
ZBIO CG ONCOLOGY INC
TLX ORUKA THERAPEUTICS INC
MAZE BICARA THERAPEUTICS INC.
JBIO ZENAS BIOPHARMA INC.
TELIX PHARMACEUTICALS LIMITED
MAZE THERAPEUTICS INC
JADE BIOSCIENCES INC
Michael Piccolo
  • Michael Piccolo

Daily Recap: SSTK/GETY, ACLX/GILD, VRE, UHG, EHAB, JMAT/HON, FBIN, MRK...

Arcellx, Inc. (ACLX - $64.11) and Gilead Sciences, Inc. (GILD - $151.40)Announces $7.8 Billion All-Cash Acquisition; Offer Value $115/share + $5 CVR; Expected Close 2Q'2026.GILD announced it has entered into a definitive agreement to acquire ACLX for $115 per share in cash at closing plus one CVR o

Carole Braudeau
  • Carole Braudeau

Credit Morning 02/23/2026

Eutelsat intends to issue € 1.5bn of new bonds due in 2031 and in 2033|

ResearchPool Subscriptions

Get the most out of your insights

Get in touch